The Expert Consensus Decision Pathway1 provides clinical workflows for treatment of patients in whom nonstatin medications may be considered in the setting of maximally tolerated statin therapy. The objective was to provide guidance for clinicians in light of new data from randomized clinical trials published since the 2013 guidelines and given approval by the US Food and Drug Administration of PCSK9 inhibitors in 2015. The Expert Consensus Panel addressed 3 questions:
Lloyd-Jones DM. Role of Nonstatin Therapies for Low-Density Lipoprotein Cholesterol Lowering in Management of Atherosclerotic Cardiovascular Disease Risk. JAMA Cardiol. 2017;2(2):218–219. doi:https://doi.org/10.1001/jamacardio.2016.4640
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: